EUVIMEDEUVIMED entdecken
Crossref

Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity

Heba T Abdel-Mohsen, Yasmin M Syam, Mahmoud S Abd El-Ghany, Somaia S Abd El-Karim

Archiv der Pharmazie · 2024-10 · 357 (10)

DOI: 10.1002/ardp.202300721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 23.07.2024. Verfasst von Heba T Abdel-Mohsen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Benzimidazoles, Cyclin-Dependent Kinase 2, Drug Screening Assays, Antitumor. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: The National Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new series of benzimidazole‐oxindole hybrids 8a–x was discovered as dual cyclin‐dependent kinase (CDK2) and glycogen synthase kinase‐3‐beta (GSK‐3β) inhibitors with potent anticancer activity. The synthesized hits displayed potent anticancer activity against national cancer institute cancer cell lines in single‐dose and five‐dose assays. Moreover, the derivatives 8k , 8l , 8n, 8o , and 8p demonstrated potent cytotoxic activity against PANC‐1 cells with IC 50 = 1.88–2.79 µM. In addition, the hybrids 8l , 8n , 8o , and 8p displayed potent antiproliferative activity on the MG‐63 cell line (IC 50 = 0.99–1.90 µM). Concurrently, the benzimidazole‐oxindole hybrid 8v exhibited potent dual CDK2/GSK‐3β inhibitory activity with IC 50 values of 0.04 and 0.021 µM, respectively. In addition, 8v displayed more than 10‐fold higher selectivity toward CDK2 and GSK‐3 β over CDK1, CDK5, GSK‐3α, vascular endothelial growth factor receptor‐2, and B‐rapidly accelerated fibrosarcoma. Screening of the effect of 8n and 8v on the cell cycle and apoptosis of PANC‐1 and MG‐63 cells displayed their ability to arrest their cell cycle at the G2‐M phase and to potentiate the apoptosis of both cell lines. In silico docking of the benzimidazole‐oxindole hybrid 8v into the catalytic pocket of both CDK2 and GSK‐3β revealed its perfect fitting through the formation of hydrogen bonding and hydrophobic interactions with the key amino acids in the binding sites. In addition, in silico absorption, distribution, metabolism, excretion studies proved that 8a–x exhibit satisfactory drug‐likeness properties for drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBenzimidazolesCyclin-Dependent Kinase 2Drug Screening Assays, AntitumorGlycogen Synthase Kinase 3 betaOxindolesHumansApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugMolecular Docking SimulationMolecular StructureProtein Kinase InhibitorsStructure-Activity Relationship

Stichwörter der Autor:innen

anticancer activitybenzimidazole‐oxindoledocking studiesdual CDK2/GSK‐3β activity

Substanzen

2-oxindoleAntineoplastic AgentsBenzimidazolesCDK2 protein, humanCyclin-Dependent Kinase 2Glycogen Synthase Kinase 3 betaOxindolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt.
  • Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt.
  • Cell Culture Unit, Nawah Scientific, El Mokattam, Cairo, Egypt.

Förderung

  • The National Research Centre

Zitieren

APA

Abdel-Mohsen, H. T., Syam, Y. M., Abd El-Ghany, M. S., & Abd El-Karim, S. S. (2024). Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity. Archiv der Pharmazie, 357(10). https://doi.org/10.1002/ardp.202300721

Vancouver

Abdel-Mohsen HT, Syam YM, Abd El-Ghany MS, Abd El-Karim SS. Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity. Archiv der Pharmazie. 2024;357(10). doi:10.1002/ardp.202300721

BibTeX
@article{AbdelMohsen2024,
  author = {Abdel-Mohsen, Heba T and Syam, Yasmin M and Abd El-Ghany, Mahmoud S and Abd El-Karim, Somaia S},
  title = {Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity},
  journal = {Archiv der Pharmazie},
  year = {2024},
  volume = {357},
  number = {10},
  doi = {10.1002/ardp.202300721}
}
Kostenlos starten →